Novartis presented data showing its LCZ696 heart drug reduced cardiovascular deaths by 20% when compared with a rival treatment, suggesting the Swiss group has a multibillion-dollar product in the making.
from WSJ.com: US Business http://ift.tt/1u9vWQ5
via IFTTT
from WSJ.com: US Business http://ift.tt/1u9vWQ5
via IFTTT
No comments:
Post a Comment